Location History:
- Higashi-Hiroshima-shi, Hiroshima, JP (1997)
- Hiroshima, JP (1998)
Company Filing History:
Years Active: 1997-1998
Title: Mutsumi Inamatsu: Innovator in Hair Follicle Research
Introduction
Mutsumi Inamatsu is a notable inventor based in Hiroshima, Japan. She has made significant contributions to the field of hair follicle research, holding 2 patents that focus on innovative methods for culturing dermal papilla cells and producing monoclonal antibodies specific to hair follicles.
Latest Patents
One of her latest patents is a method for long-term subculture of dermal papilla cells. This invention provides a technique for culturing dermal papilla cells alongside mammalian epidermal cells from various parts of a mammal. The method ensures the long-term stability of dermal papilla cells while maintaining their original function. Another significant patent is a method for producing monoclonal antibodies specific to hair follicles. This invention outlines a process that includes freezing hair bulbs from follicles, immunizing an animal, and fusing cells to create hybridomas that produce antibodies. These antibodies are crucial for functional analysis of hair follicles and developing new diagnostic and therapeutic approaches for conditions like alopecia.
Career Highlights
Mutsumi Inamatsu has worked with the Research Development Corporation of Japan, where she has contributed to various research initiatives. Her work has been instrumental in advancing the understanding of hair follicle biology and its applications in medicine.
Collaborations
Throughout her career, Mutsumi has collaborated with notable individuals such as Takashi Matsuzaki and Katsutoshi Yoshizato. These collaborations have further enriched her research and innovations in the field.
Conclusion
Mutsumi Inamatsu's contributions to hair follicle research through her innovative patents highlight her role as a leading inventor in this specialized area. Her work continues to pave the way for advancements in hair-related therapies and diagnostics.